Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Weighted Average) (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $50.2 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 5.63% year-over-year to $50.2 million; the TTM value through Dec 2025 reached $50.2 million, up 5.63%, while the annual FY2025 figure was $50.2 million, 5.63% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $50.2 million in Q4 2025 per MIRM's latest filing, up from $49.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $50.2 million in Q4 2025 and bottomed at $30.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $39.8 million, with a median of $38.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 3.96% in 2022, then grew 24.56% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $30.3 million in 2021, then increased by 11.6% to $33.8 million in 2022, then grew by 20.82% to $40.9 million in 2023, then rose by 16.23% to $47.5 million in 2024, then rose by 5.63% to $50.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $50.2 million in Q4 2025, $49.8 million in Q3 2025, and $49.7 million in Q2 2025.